GC-globulin: a first-in-class extracellular allosteric modulator of GLP-1 receptor signalling
GC-globulin is a naturally occurring extracellular allosteric modulator that enhances GLP-1 receptor signalling. Preclinical studies demonstrate synergistic glucose lowering, reduced food intake and weight loss with GLP-1 receptor agonists, supporting enhanced efficacy at lower agonist doses.
This first-in-class platform enables extracellular modulation of GPCR signalling across multiple receptor families.
Applications: Type 2 diabetes, obesity, MASLD, neurodegenerative disease
| Features | Benefits |
|---|---|
| First endogenous extracellular modulator of GLP-1R | Novel mechanism with strong differentiation from existing GLP-1 therapies |
| Synergistic activity with GLP-1 receptor agonists | Potential to improve efficacy while reducing agonist dose |
| Compatible with existing GLP-1 drug class | Applicable to marketed and next-generation incretin therapeutics |
| Cryo-EM and mechanistic studies identify a defined extracellular binding interface | Enables rational optimisation and engineering of next-generation molecules |
| Broad therapeutic potential across metabolic disease | Opportunities beyond diabetes, including obesity, MASLD and neurodegeneration |
Patented and Available For
- Co-development
- Consulting
- Licensing